Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Pittsburgh, Pennsylvania 15224


RATIONALE: Alemtuzumab, tacrolimus, and methylprednisolone may be an effective treatment for graft-versus-host disease caused by a donor stem cell transplant. PURPOSE: This phase II trial is studying how well giving alemtuzumab together with tacrolimus and methylprednisolone works in treating acute graft-versus-host disease in patients who have undergone donor stem cell transplant.

Study summary:

OBJECTIVES: Primary - Determine the 4-week rate of complete response in patients with severe acute graft-vs-host disease (GVHD) treated with alemtuzumab, tacrolimus, and methylprednisolone within 100 days after undergoing allogeneic stem cell transplantation. Secondary - Determine the best response at 4 and 12 weeks in patients treated with this regimen. - Determine 6-month survival of patients treated with this regimen. - Determine the rate of infectious complications in patients treated with this regimen. - Determine rate of chronic GVHD in patients treated with this regimen. OUTLINE: This is an open-label, single-blind, multicenter study. Patients receive methylprednisolone IV on days 1-3 and then orally or IV on days 4-14; tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease; and alemtuzumab IV over 2 hours on days 4-6, 18, and 32. Treatment continues in the absence of unacceptable toxicity or the development of serious infection. After completion of study treatment, patients are followed at 2 and 4 weeks. PROJECTED ACCRUAL: A total of 9-34 patients will be accrued for this study within 8-12 months.


DISEASE CHARACTERISTICS: - Diagnosis of acute graft-vs-host disease (GVHD) - Clinical grade C or D disease - No grade C disease with single organ skin involvement - Has undergone allogeneic stem cell transplantation within the past 100 days - Absolute neutrophil count > 500/mm^3 (donor-derived [> 60% by peripheral blood lymphocyte chimerism analyses]) - No development of GVHD after prior donor lymphocyte infusion - Must have received prior prophylactic cyclosporine or tacrolimus at the onset of acute GVHD PATIENT CHARACTERISTICS: Age - Over 18 Performance status - Not specified Life expectancy - Not specified Hematopoietic - See Disease Characteristics Hepatic - No serologic evidence of active hepatitis B or C infection Renal - Creatinine ≤ 3.5 mg/dL - No requirement for dialysis Cardiovascular - No requirement for vasopressors Pulmonary - No requirement for a ventilator Other - Not pregnant - Negative pregnancy test - Fertile patients must use effective contraception during and for 6 months after completion of study treatment - No known HIV positivity - No active uncontrolled infection - No other organ dysfunction PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified



Primary Contact:

Principal Investigator
Mary Laughlin, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Backup Contact:


Location Contact:

Pittsburgh, Pennsylvania 15224
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.